SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

Alfaxan Multidose 4%

ZTS·Zoetis Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (10 mg/mL); Research/Preclinical (4% formulation)
Time to market
The standard 10 mg/mL formulation is already on the market. The 4% concentrated formulation appears to be an experimental/research-stage product with no publicly disclosed regulatory submission or commercialization timeline.
Why 3/10
No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for the 4% formulation in the next 12 months. The standard 10 mg/mL product is already approved and commercialized. Alfaxan is one small product within Zoetis's massive diversified portfolio (~$9.5B revenue), so even a label expansion would have negligible impact on ZTS shares.
Actionable Insight NEUTRAL

Alfaxan Multidose 4% has no scheduled regulatory decision or pivotal readout in the next 12 months. The standard 10 mg/mL formulation is already marketed. Watch for any FDA submission or label expansion for the 4% concentrated formulation, but none is currently visible. Zoetis's stock moves on company-wide earnings and its large dermatology/parasiticide portfolio, not on this single anesthetic product.

Price Chart

Loading chart...

Executive Summary

Alfaxan Multidose 4% is a concentrated (40 mg/mL, 4% w/v) experimental formulation of alfaxalone, a neuroactive steroid injectable anesthetic for veterinary use. The standard Alfaxan Multidose (10 mg/mL) is FDA-approved for dogs and cats (NADA 141-342, originally 2012, multidose version approved June 2018) and indexed for minor species (Alfaxan Multidose IDX, February 2020). The 4% formulation (development code RD0387) was developed by Jurox, which Zoetis acquired in 2022, and has been studied in research settings for intramuscular sedation in dogs and wildlife immobilization, but it does not appear to have a separate FDA approval or commercial launch in the US. For Zoetis (NYSE: ZTS), a $9.5B+ revenue animal health giant, Alfaxan is a modest product within a vast portfolio and the 4% variant is a niche R&D project with no near-term binary catalyst.

How It Works

Alfaxalone is a synthetic steroid that binds to GABA-A receptors in the brain and spinal cord, enhancing the effect of the body's natural calming signals. This produces general anesthesia (loss of consciousness) and sedation. It is injected intravenously or intramuscularly to sedate or anesthetize animals for veterinary procedures.

Trial Status

The standard Alfaxan Multidose (10 mg/mL) is FDA-approved and commercially marketed for dogs and cats. The Alfaxan Multidose IDX variant is indexed for minor species (exotic animals, birds, reptiles, fish, etc.). The 4% (40 mg/mL) concentrated formulation (RD0387) has been evaluated in published research studies for intramuscular sedation in dogs and wildlife immobilization but has not progressed to a registrational clinical trial or FDA submission visible in public sources.

The Two-Sided Case

▲ Bull Case4
Alfaxalone is a well-established veterinary anesthetic with a strong safety profile and is the leading anesthetic product in its class globally.
The 4% concentrated formulation allows smaller injection volumes, which is advantageous for wildlife and exotic animal sedation where large volumes are impractical.
Zoetis acquired Jurox (and Alfaxan) in 2022, and the product benefits from Zoetis's global commercial infrastructure and distribution network.
The product has a 56-day in-use shelf life and requires no refrigeration, making it convenient for veterinary practices.
▼ Bear Case4
The 4% concentrated formulation appears to still be in the research phase with no clear FDA submission or commercialization timeline visible.
Alfaxan is a very small product within Zoetis's massive portfolio; Zoetis has dozens of products with over $100M in annual revenue, making Alfaxan immaterial to the stock's performance.
Zoetis faces competitive pressure in its core dermatology franchise (Apoquel, Cytopoint), which are the real value drivers, and the company's Q3 2026 revenue declined 1% year-over-year.
Several large institutional holders trimmed or exited ZTS positions in Q2 2026, and the stock has fallen from a 52-week high of $132.49 to ~$79, reflecting broader headwinds.

Upcoming Catalysts

  • No scheduled regulatory or clinical catalysts identified for the 4% formulation

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zoetis Inc. 8-K ZTS ·Originating report

Sources · 10

Hover a chip for the title
1 zoetisus.com2 dailymed.nlm.nih.gov3 fda.gov4 animaldrugsatfda.fda.gov5 news.zoetis.com6 onlinelibrary.wiley.com7 sciencedirect.com8 zoetisus.com9 investor.zoetis.com10 stockanalysis.com